Effects of agonists of peroxisome proliferator-activated receptor γ on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro
Objective To examine the effects of agonists of peroxisome proliferator-activated receptor (PPAR) γ on proteoglycan degradation induced by interleukin (IL)-1β or tumor necrosis factor (TNF)α in cartilage in vitro. Design Proteoglycan degradation was measured as release of radioactivity from rat cart...
Gespeichert in:
Veröffentlicht in: | Osteoarthritis and cartilage 2002-09, Vol.10 (9), p.673-679 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective To examine the effects of agonists of peroxisome proliferator-activated receptor (PPAR) γ on proteoglycan degradation induced by interleukin (IL)-1β or tumor necrosis factor (TNF)α in cartilage in vitro.
Design Proteoglycan degradation was measured as release of radioactivity from rat cartilage explants previously labeled with 35SO2−4. Western blots were used to examine tissue levels of aggrecan neoepitopes NITEGE and VDIPEN, generated by aggrecanases and matrix metalloproteinases (MMP), respectively. Production of MMP-2, -3 and -9 by cultured rat chondrocytes was measured by zymography and by fluorimetric assay.
Results IL-1β-induced proteoglycan degradation was likely due to aggrecanase, since it was associated with a strong increase of NITEGE signal. MMP-dependent VDIPEN signal increased only after further incubation with pro-MMP activator APMA. PPAR agonists 15d-PGJ2 and GI262570 (10μM) inhibited IL-1β- and TNFα-induced proteoglycan degradation measured both before and after addition of APMA. The agonists also inhibited cytokine-induced MMP production by isolated chondrocytes.
Conclusion This study shows that PPARγ agonists inhibit cytokine-induced proteoglycan degradation mediated by both aggrecanase and MMP. This effect is associated with inhibition of production of MMP-3 and -9. These results support the interest for PPARγ agonists as candidate inhibitors of pathological cartilage degradation. Copyright 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved. |
---|---|
ISSN: | 1063-4584 1522-9653 |
DOI: | 10.1053/joca.2002.0827 |